 |
|
Effects of Vitreomacular Traction on Ranibizumab Treatment Response in Eyes with Neovascular Age-related Macular Degeneration
Kang Hoon Lee, Hee Seung Chin, Na Rae Kim, Yeon Sung Moon
Korean J Ophthalmol. 2015;29(6):396-403. Published online 2015 Nov 25 DOI: https://doi.org/10.3341/kjo.2015.29.6.396
|
|
Citations to this article as recorded by
 Prognostic factors associated with the course of vitreomacular traction in eyes with age-related macular degeneration
Rüveyde Garip, Ayça K Çınar, Abdulkadir C Çınar, Ahmet Kürşad Sakallıoğlu, Hande Güçlü, Vuslat Gürlü
Photodiagnosis and Photodynamic Therapy.2022; 40: 103025. CrossRef OCT Biomarkers in Neovascular Age-Related Macular Degeneration: A Narrative Review
Cristian Metrangolo, Simone Donati, Marco Mazzola, Liviana Fontanel, Walter Messina, Giulia D’alterio, Marisa Rubino, Paolo Radice, Elias Premi, Claudio Azzolini, Serena Fragiotta
Journal of Ophthalmology.2021; 2021: 1. CrossRef Effect of conbercept or ranibizumab in the treatment of wet age-related macular degeneration
Dawei Zhang, Zahrah Khan, Tao Chai
Environmental Disease.2019; 4(2): 50. CrossRef Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded?
Kleanthis Manousaridis, Silvia Peter-Reichart, Stefan Mennel
Graefe's Archive for Clinical and Experimental Ophthalmology.2017; 255(10): 1907. CrossRef Vitreomacular adhesion or vitreomacular traction may affect antivascular endothelium growth factor treatment for neovascular age-related macular degeneration
Ping Xie, Xinhua Zheng, Yingqing Yu, Xiaojian Ye, Zizhong Hu, Dongqing Yuan, Qinghuai Liu
British Journal of Ophthalmology.2017; 101(8): 1003. CrossRef
|